---
title: "Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295100157.md"
description: "On August 6th, 2026, Avalo Therapeutics, Inc. (Nasdaq: AVTX), headquartered in Wayne, PA, revealed their business developments and financial outcomes for the second quarter of the year. This clinical stage biotech firm focuses on creating treatments that aim at the IL-1β pathway to combat immune-mediated inflammatory illnesses."
datetime: "2026-08-06T11:04:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295100157.md)
  - [en](https://longbridge.com/en/news/295100157.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295100157.md)
generator: "portal-rs"
---

# Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

On August 6th, 2026, Avalo Therapeutics, Inc. (Nasdaq: AVTX), headquartered in Wayne, PA, revealed their business developments and financial outcomes for the second quarter of the year. This clinical stage biotech firm focuses on creating treatments that aim at the IL-1β pathway to combat immune-mediated inflammatory illnesses.

### Related Stocks

- [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md)

## Related News & Research

- [Avalo Therapeutics CFO Christopher Ryan Sullivan disposes of common shares worth $1.44 million](https://longbridge.com/en/news/296395368.md)
- [Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 5.9%  - Still a Buy?](https://longbridge.com/en/news/297078386.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [10:31 ETLiver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight](https://longbridge.com/en/news/296802956.md)
- [JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis | ROIV Stock News](https://longbridge.com/en/news/297068196.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**